Literature DB >> 24346428

[Therapeutic drug monitoring in psychiatry. A brief summary of the new consensus paper by the task force on TDM of the AGNP].

G Gründer1, P Baumann, A Conca, G Zernig, C Hiemke.   

Abstract

In October 2011 the Task Force Therapeutic Drug Monitoring of the Association for Neuropsychopharmacology and Pharmacopsychiatry (AGNP) published an update (Pharmacopsychiatry 2011, 44: 195-235) of the first version of the consensus paper on therapeutic drug monitoring (TDM) published in 2004. This article summarizes the essential statements to make them accessible to a wider readership in German speaking countries.

Mesh：

Substances：

Year:  2014        PMID： 24346428     DOI： 10.1007/s00115-013-3925-2

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  6 in total

Review 1.  Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau".

Authors:  Finn Bengtsson
Journal:  Ther Drug Monit       Date:  2004-04       Impact factor: 3.681

Review 2.  Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging.

Authors:  G Gründer; C Hiemke; M Paulzen; T Veselinovic; I Vernaleken
Journal:  Pharmacopsychiatry       Date:  2011-09-28       Impact factor: 5.788

3.  [Expanding therapeutic reference ranges using dose-related reference ranges].

Authors:  E Haen; C Greiner; W Bader; M Wittmann
Journal:  Nervenarzt       Date:  2008-05       Impact factor: 1.214

Review 4.  [Basic principles of therapy with neuropsychotropic drugs].

Authors:  G Gründer; T Veselinović; M Paulzen
Journal:  Nervenarzt       Date:  2012-09       Impact factor: 1.214

5.  AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

Authors:  C Hiemke; P Baumann; N Bergemann; A Conca; O Dietmaier; K Egberts; M Fric; M Gerlach; C Greiner; G Gründer; E Haen; U Havemann-Reinecke; E Jaquenoud Sirot; H Kirchherr; G Laux; U C Lutz; T Messer; M J Müller; B Pfuhlmann; B Rambeck; P Riederer; B Schoppek; J Stingl; M Uhr; S Ulrich; R Waschgler; G Zernig
Journal:  Pharmacopsychiatry       Date:  2011-09-27       Impact factor: 5.788

Review 6.  The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.

Authors:  P Baumann; C Hiemke; S Ulrich; G Eckermann; I Gaertner; M Gerlach; H-J Kuss; G Laux; B Müller-Oerlinghausen; M L Rao; P Riederer; G Zernig
Journal:  Pharmacopsychiatry       Date:  2004-11       Impact factor: 5.788
  6 in total
  4 in total

1.  [The CIMH track concept in the treatment of psychotic disorders].

Authors:  Dusan Hirjak; Peter Gass; Michael Deuschle; F Markus Leweke; Andreas Böhringer; Nadine Schenkel; Doris Borgwedel; Marco Heser; Antje Breisacher; Andreas Meyer-Lindenberg
Journal:  Nervenarzt       Date:  2020-03       Impact factor: 1.214

Review 2.  [Pharmacogenetics in psychiatry: state of the art].

Authors:  D J Müller; E J Brandl; F Degenhardt; K Domschke; H Grabe; O Gruber; J Hebebrand; W Maier; A Menke; M Riemenschneider; M Rietschel; D Rujescu; T G Schulze; L Tebartz van Elst; O Tüscher; J Deckert
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

Review 3.  [Genetic tests for controlling treatment with antidepressants].

Authors:  T Bschor; C Baethge; C Hiemke; B Müller-Oerlinghausen
Journal:  Nervenarzt       Date:  2017-05       Impact factor: 1.214

4.  Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study.

Authors:  Katrin Ruppert; Christoph Geffert; Hans-Willi Clement; Christian Bachmann; Michael Haberhausen; Eberhard Schulz; Christian Fleischhaker; Monica Biscaldi-Schäfer
Journal:  J Neural Transm (Vienna)       Date:  2022-04-07       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.